EcoDrugPlus

Gamma-Aminobutyric Acid Type A Receptor Subunit Epsilon

Ensembl ID : ENSVVUG00000029050
Gene Symbol: GABRE
3 Cross references
109 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Subunit Gamma3

Ensembl ID : ENSVVUG00000008676
Gene Symbol: GABRG3
1 Cross references
249 Possible Orthologues:

Gamma-Aminobutyric Acid Type A Receptor Theta Subunit

Ensembl ID : ENSVVUG00000029074
Gene Symbol: GABRQ
3 Cross references
87 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 1

Ensembl ID : ENSVVUG00000001839
Gene Symbol: GABBR1
3 Cross references
264 Possible Orthologues:

Gamma-Aminobutyric Acid Type B Receptor Subunit 2

Ensembl ID : ENSVVUG00000019660
Gene Symbol: GABBR2
3 Cross references
241 Possible Orthologues:

Gastric Inhibitory Polypeptide Receptor

Ensembl ID : ENSVVUG00000003197
Gene Symbol: GIPR
3 Cross references
93 Possible Orthologues:

Glucagon Like Peptide 1 Receptor

Ensembl ID : ENSVVUG00000026496
Gene Symbol: GLP1R
3 Cross references
133 Possible Orthologues:

Glucagon Like Peptide 2 Receptor

Ensembl ID : ENSVVUG00000028914
Gene Symbol: GLP2R
3 Cross references
205 Possible Orthologues:

Glucagon Receptor

Ensembl ID : ENSVVUG00000020015
Gene Symbol: GCGR
3 Cross references
183 Possible Orthologues:

Glucokinase

Ensembl ID : ENSVVUG00000008505
Gene Symbol: GCK
1 Cross references
211 Possible Orthologues:

Glucosidase Alpha, Acid

Ensembl ID : ENSVVUG00000017970
Gene Symbol: GAA
3 Cross references
234 Possible Orthologues:

Glucosylceramidase Beta 1

Ensembl ID : ENSVVUG00000003843
Gene Symbol: GBA1
3 Cross references
254 Possible Orthologues:

Select Keywords:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).